Jupiter Endo Hires New Chief Medical Officer

Jupiter Endovascular has appointed renowned interventional cardiologist Catalin Toma, MD as its new chief medical officer. The newly created role has a global scope.

Dr. Toma brings extensive clinical and research experience in structural heart and interventional cardiology to the Menlo Park, California-based endovascular interventions company. He serves as Director of Interventional Cardiology at UPMC Heart and Vascular Institute, Associate Professor of Medicine at the University of Pittsburgh School of Medicine, and leads UPMC Presbyterian Hospital’s Chronic Total Occlusion Program.

He has co-led clinical studies of Jupiter’s Vertex thrombectomy system and other interventional technologies and holds several patents.

Vertex uses the company’s Transforming Fixation (TFX) platform to navigate the right heart and stabilize in the pulmonary arteries for controlled intervention. The technology separates flexible navigation from stable support, addressing challenges in pulmonary embolism thrombectomy while supporting clot removal and hemodynamic recovery.

Earlier this month, Jupiter Endo released results from its SPIRARE II pivotal trial evaluating Vertex for acute, intermediate-risk pulmonary embolism. The trial met both primary endpoints, showing meaningful heart recovery and clinical safety.

Comments from Jupiter Endo execs

Carl J. St. Bernard, CEO: “Dr. Toma is a globally recognized physician, researcher and leader in interventional cardiovascular medicine. His experience treating patients with complex pulmonary vascular and structural heart disease, combined with his deep understanding of the clinical evidence required to advance new therapies, will be invaluable as we realize the potential of our TFX platform. We are delighted to welcome him as our chief medical officer.”

Dr. Toma: “Jupiter Endovascular is addressing a long-standing challenge in cardiovascular intervention, which is balancing the competing needs of flexibility and stability in your catheters without creating cardiac distress in unstable patients. I have seen the capabilities of the company’s TFX technology in the Vertex System that enables one catheter to change its state from flexible to fixed, and back again, firsthand in the SPIRARE II trial and am very encouraged about its potential to enable us to do more than we can today with current commercial technologies. I’m also energized by the company’s vision to look beyond clot removal to the restoration of patient hemodynamics and right-heart recovery with the intent to improve long-term prospects for PE patients.”